Evidence map›Paper›PMID 33073228›Full record

ArticleVaccine: X2020

The economic burden of measles in children under five in Uganda.

Gatien De Broucker, Anthony Ssebagereka, Rebecca Racheal Apolot, Mutebi Aloysius, Elizabeth Ekirapa Kiracho, Bryan Patenaude, Dagna Constenla

Abstract read
In one paragraph

Article in Vaccine: X, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gatien De BrouckerInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, United States.
Anthony SsebagerekaMakerere University School of Public Health, Uganda.
Rebecca Racheal ApolotMakerere University School of Public Health, Uganda.
Mutebi AloysiusMakerere University School of Public Health, Uganda.
Elizabeth Ekirapa KirachoMakerere University School of Public Health, Uganda.
Bryan PatenaudeInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, United States.
Dagna ConstenlaInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is very limited evidence about the economic cost of measles in low-income countries. We estimated the cost of treating measles in Uganda from a societal perspective.

methodsWe conducted an incidence-based cost-of-illness study in Uganda. We surveyed the facility staff, recording hospital-related expenditures for measles patients. We interviewed caregivers of children with measles at 48 selected healthcare facilities. We conducted phone interviews with caregivers 7-14 days post-discharge to capture additional out-of-pocket expenses and time costs.

resultsFrom a societal perspective, a hospitalized and an ambulatory episode of measles cost 2018 US$ 60 and $15, respectively. The government spent on average $12 and $5 per hospitalized and ambulatory episode of measles. Including both public and private facilities, caregivers incurred approximately $44 in economic costs, including $23 in out-of-pocket expenses. In 2018, 2614 cases of measles were confirmed, resulting in $135,627 in societal costs, including $59,357 in economic costs to Ugandan households.

conclusionThis cost-of-illness study is the first to use empirical methods to quantify the economic burden of measles in a low-income country. Information related to the cost of treating measles is important for guiding decisions related to changes in measles control and prevention.

Indexed as

Cost-of-illnessEconomic benefit of immunizationEconomic burdenMeaslesOutbreakUgandaVaccine-preventable disease

Identifiers

PMID33073228
PMCPMC7548439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.